Skip to Content

Denileukin Diftitox Dosage

Applies to the following strength(s): 150 mcg/mL

The information at is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.

Usual Adult Dose for:

Additional dosage information:

Usual Adult Dose for Lymphoma

9 mcg/kg/day or 18 mcg/kg/day by IV infusion over 30 to 60 minutes for 5 consecutive days every 21 days for 8 cycles.

-Pre-medicate with an antihistamine and acetaminophen prior to each infusion.
-Withhold treatment if serum albumin levels are less than 3.0 g/dL.
-Discontinue for adverse infusion reactions.
-Do not administer as a bolus injection.

Use: Treatment of persistent or recurrent cutaneous T-cell lymphoma whose malignant cells express the CD25 component of the IL-2 receptor.

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available


-SERIOUS INFUSION REACTIONS: Serious and fatal infusion reactions have been reported. Administer this drug in a facility equipped and staffed for cardiopulmonary resuscitation. Immediately stop and permanently discontinue this drug for serious infusion reactions.
-CAPILLARY LEAK SYNDROME: Capillary leak syndrome resulting in death has been reported. Monitor weight, edema, blood pressure, and serum albumin levels prior to and during treatment.
-LOSS OF VISUAL ACUITY: Loss of visual acuity and color vision have been reported.

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.


Data not available

Other Comments

Administration advice:
-Do not mix this drug with other medications.
-Do not administer this drug through an in-line filter.
-Administer prepared solutions within 6 hours, using a syringe pump or IV infusion bag.

Reconstitution/preparation techniques:
-Consult manufacturer's product information.

-Doses of approximately twice the recommended dose (31 mcg/kg/day) resulted in moderate-to-severe nausea, vomiting, fever, chills, and/or persistent asthenia.
-Up to 100% of patients tested positive for denileukin diftitox antibodies after 3 courses of treatment.

Cardiovascular: Weight, edema, blood pressure
Laboratory: Serum albumin levels (prior to initiation of each course and more often as clinically indicated)
Ocular: Visual acuity, color vision
Oncologic: CD25 expression of malignant cells (prior to treatment initiation)
Other: Infusion reactions (within 24 hours of infusion administration)

Patient advice:
-Weigh yourself daily and contact your health care provider immediately if you experience rapid weight gain.